Featured Research

from universities, journals, and other organizations

Next decade offers promise for treatment of spinal cord injuries

Date:
April 4, 2010
Source:
American Academy of Orthopaedic Surgeons
Summary:
Although new developments in the management of spinal cord injuries (SCI) are on the horizon, any eventual cure for the condition is more likely to involve a multidisciplinary approach, drawing from expertise in several fields, according to new research.

Although new developments in the management of spinal cord injuries (SCI) are on the horizon, any eventual cure for the condition is more likely to involve a multidisciplinary approach, drawing from expertise in several fields, according to a review article published in the April 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

  • Each year, approximately 12,000 men and women sustain and survive spinal cord injuries, and about 259,000 Americans currently live with a long-lasting SCI.
  • Although traditionally associated primarily with young adults, today the average age of SCI patients has risen to 40.2 years.
  • Automobile crashes are the most common cause of SCI, and males are most often affected, comprising almost 81 percent of all SCI patients.

According to Ranjan Gupta, MD, chair of the department of orthopaedic surgery and professor of orthopaedic surgery, anatomy and neurobiology, and biomedical engineering at the University of California, Irvine, newer therapeutic approaches including stem cell therapy and novel drug formulations, hold special promise for management of SCI patients.

"Yet, spinal cord injuries are especially difficult to treat because they involve more than a direct injury to the spine," noted Dr. Gupta. "The primary mode of an SCI involves changes to the patient's anatomy that occur as the result of the actual traumatic event. Secondary injuries may occur as a result of how the body responds to the primary injury, usually by producing scar tissue that can make treatment problematic."

Dr. Gupta added that it is in the area of these secondary injuries that there are many promising areas of research, from optimizing the acute management of the patient to pharmacologic interventions to cellular transplantation.

"Yet, to maximize the chances for recovery after SCI, early surgical intervention is essential," he stated.

With the sustained, robust attention from scientists and clinicians, as well as the continued active support from the National Institutes of Health, there should be substantial changes in the clinical management of SCI over the next decade. "As long as the field is being actively researched, there is cause for renewed and continued hope," Dr. Gupta continued.

"Patients with spinal cord injuries face possible significant neurologic problems, resulting in paralysis and other disabilities. Innovative treatment strategies such as stem cell transplantation have enjoyed renewed interest under the current administration," Dr. Gupta noted.

"Currently, the FDA has been more receptive to cellular transplantation trials, with one of the first trials being actively planned in the next two years," he said. "While there have been several animal studies showing benefits from various pharmacological interventions, the human clinical trials are still pending."

Dr. Gupta noted ongoing clinical trials -- including the Surgical Treatment of Acute Spinal Cord Injury Study (STASCIS) -- continue to explore new approaches to the management of SCI, including multidiscplinary approaches that rely on several specialties to shape a successful treatment.

"It is extremely unlikely that SCI will respond to one single intervention, or that there will be a 'magic bullet,' " he concluded. "Rather, the treatment of SCI will undoubtedly require a multidisciplinary approach and management."


Story Source:

The above story is based on materials provided by American Academy of Orthopaedic Surgeons. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gupta, Ranjan, Bathen, Mary E., Smith, Jeremy S., Levi, Allan D., Bhatia, Nitin N., Steward, Oswald. Advances in the Management of Spinal Cord Injury. Journal of the American Academy of Orthopaedic Surgeons, 2010; 18: 210-222 [link]

Cite This Page:

American Academy of Orthopaedic Surgeons. "Next decade offers promise for treatment of spinal cord injuries." ScienceDaily. ScienceDaily, 4 April 2010. <www.sciencedaily.com/releases/2010/04/100401130238.htm>.
American Academy of Orthopaedic Surgeons. (2010, April 4). Next decade offers promise for treatment of spinal cord injuries. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100401130238.htm
American Academy of Orthopaedic Surgeons. "Next decade offers promise for treatment of spinal cord injuries." ScienceDaily. www.sciencedaily.com/releases/2010/04/100401130238.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins